| Sign In to gain access to subscriptions and/or personal tools. |
Upregulation of ADAM-17 expression in active lesions in multiple sclerosisBiomedical Research Centre, Sheffield Hallam University, Howard St, Sheffield S1 1WB, UK, j.plumb{at}shu.ac.uk
Neuropathology Laboratory, Department of Pathology, Royal Group of Hospitals Trust, Grosvenor Road, Belfast, Northern Ireland, UK
Biomedical Research Centre, Sheffield Hallam University, Howard St, Sheffield S1 1WB, UK
Biomedical Research Centre, Sheffield Hallam University, Howard St, Sheffield S1 1WB, UK
Biomedical Research Centre, Sheffield Hallam University, Howard St, Sheffield S1 1WB, UK
Biomedical Research Centre, Sheffield Hallam University, Howard St, Sheffield S1 1WB, UK
Biomedical Research Centre, Sheffield Hallam University, Howard St, Sheffield S1 1WB, UK ADAM-17, a disintegrin and metalloproteinase, is the major proteinase responsible for the cleavage of membrane-bound tumour necrosis factor (TNF) as well as being an active sheddase of other cytokines, cytokine receptors, growth factors and adhesion molecules. TNF is a major proinflammatory cytokine that has been identified as having a pathogenic role in inflammatory diseases within the CNS including multiple sclerosis (MS). Here we report the cellular origin and distribution of ADAM- 17 expression within clinically and neuropathologically confirmed MS and normal control white matter, assessed by immunohistochemistry, western blotting and PCR. ADAM-17 expression was associated with the blood vessel endothelium, activated macrophages/microglia and parenchymal astrocytes in MS white matter. Increased levels of ADAM-17 immunoreactivity were displayed in active lesions with evidence of recent myelin breakdown. Further studies into the functional role of ADAM-17 in the pathogenesis of MS and other inflammatory conditions are required.
Key Words: ADAM-17 adhesion molecules astrocytes endothelium multiple sclerosis TACE tumour necrosis factor
Multiple Sclerosis, Vol. 12, No. 4,
375-385 (2006) |
|||